This March we celebrated our 8th HMTRC Workshop that over the years has welcomed 62 external sites from around the world to develop and advance HP ¹³C technology for scientific investigation and ultimately patient care. A big thanks to all who presented and participated. We look forward to continued team science and collaborations. 

The two-day event held over March 17th-18th hosted many great presentations and in depth hands-on training, discussions and interactions between academia and industry. The available recorded presentation links are listed below. Many thanks to the Gold Sponsors of the event, GE Healthcare, MilliporeSigma Isotec Stable Isotopes Division, and Bruker BioSpin.

2021 was a milestone year for C-13 Pyruvate Hyperpolarization studies in humans with over 1,000 studies completed since its inception. Despite the limitations caused by the COVID epidemic worldwide, 264 studies were performed between 1 JAN and 31 DEC 2021, a 20% increase over the previous year.

As can be seen in the table below, 2 in 3 studies were conducted in patients, and 85% of these were oncology patients. Among the cancers studied, prostate and brain tumors dominate along with other solid tumors. However, it is important to note the increase in cardiac related studies, such as diabetes, cardiac functions or cardiotoxicity, for which more than half of the patients received additional injections. On the average, 30% of the volunteers and patients received more than one injection of C-13. The C-13 Pyruvate Hyperpolarization procedures were shown to be quite safe, as sites only reported mild side effects associated with the injection and no moderate or severe adverse events even after multiple administrations to the same subject.

This milestone was accomplished by the collaborative efforts of a total of 14 sites, with this year, the addition of the University of Maryland and CGMH in Taipei, Taiwan to the already impressive list of global sites.

Congratulations to all those involved as it is significant milestone in advancing this MR molecular imaging technology!

Visit the HMTRC Website Resources Page on our website for

Now available! 20+ presentations to re-watch or watch for the first time! Watch to get updates from the center, or see what

others have been doing in their HP ¹³C preclinical and clinical research.

We are currently looking for presenters for our International HP C-13 MRI Seminar. Present new findings, publications, or other work in preclinical and human research. Presentations are 25 minutes with a

5-minute Q &A. Email us at hyperpolarizedmri@ucsf.edu.

Twitter  |  Website  | Email    

Technology Dissemination |  HP Training Modules |  Publications |  Projects   

People  |  Contact Us  | Donate    

The Hyperpolarized MRI Technology Resource Center (HMTRC) is supported by the National Institute of Biomedical Imaging and Bioengineering